Publicaciones en colaboración con investigadores/as de Instituto de Salud Carlos III (10)

2024

  1. Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates

    Gut

2022

  1. Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria

    Science Translational Medicine, Vol. 14, Núm. 627

2021

  1. Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration

    Acta Neuropathologica Communications, Vol. 9, Núm. 1

2018

  1. Alterations in Gene and Protein Expression of Cannabinoid CB 2 and GPR55 Receptors in the Dorsolateral Prefrontal Cortex of Suicide Victims

    Neurotherapeutics, Vol. 15, Núm. 3, pp. 796-806

  2. Cannabinoid cb1 and cb2 receptors, and monoacylglycerol lipase gene expression alterations in the basal ganglia of patients with parkinson’s disease

    Neurotherapeutics, Vol. 15, Núm. 2, pp. 459-469

2017

  1. Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors

    Frontiers in Pharmacology, Vol. 8, Núm. OCT

2016

  1. Increased vulnerability to ethanol consumption in adolescent maternal separated mice

    Addiction Biology, Vol. 21, Núm. 4, pp. 847-858

  2. Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels

    Journal of Neurochemistry, Vol. 136, Núm. 2, pp. 403-415

2015

  1. Editorial: Parkinson’s disease: Cell vulnerability and disease progression

    Frontiers in Neuroanatomy

2009

  1. Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson's disease

    Neurobiology of Disease, Vol. 36, Núm. 3, pp. 494-508